eloralintide vs MET-233i
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
eloralintide
Developed by Eli Lilly
NCT06230523 · Phase 2 · completed
Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
Next expected readout: December 2026 · NCT07738614 (registry estimate)
Reported efficacy
Percent Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. (met)
Result source: NCT06230523
MET-233i
Developed by Pfizer and partners
NCT07022977 · Phase 1 · completed
A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.
Next expected readout: January 2027 · NCT07725809 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | eloralintide | MET-233i |
|---|---|---|
| Body weight, % change | -20.1% vs -0.4%−19.7 vs placeboNCT062305235 other results
| —Not reported |
| Weight loss of 5% or more | 92.7% vs 31.2%+61.5 vs placeboNCT062305235 other results
| —Not reported |
| Weight loss of 10% or more | 82.3% vs 12.8%+69.5 vs placeboNCT062305235 other results
| —Not reported |
| Waist circumference, change (cm) | —Trial running · NCT07321886 | —Not reported |
Body weight, % change
- eloralintide
- -20.1% vs -0.4%−19.7 vs placeboNCT06230523
5 other results
- -19.9% vs -0.4% NCT06230523
- -17.6% vs -0.4% NCT06230523
- -12.4% vs -0.4% NCT06230523
- -9.4% vs -0.4% NCT06230523
- -16.5% vs -0.4% NCT06230523
- MET-233i
- —Not reported
Weight loss of 5% or more
- eloralintide
- 92.7% vs 31.2%+61.5 vs placeboNCT06230523
5 other results
- 97.5% vs 31.2% NCT06230523
- 85.0% vs 31.2% NCT06230523
- 87.1% vs 31.2% NCT06230523
- 71.5% vs 31.2% NCT06230523
- 90.8% vs 31.2% NCT06230523
- MET-233i
- —Not reported
Weight loss of 10% or more
- eloralintide
- 82.3% vs 12.8%+69.5 vs placeboNCT06230523
5 other results
- 91.1% vs 12.8% NCT06230523
- 76.6% vs 12.8% NCT06230523
- 60.5% vs 12.8% NCT06230523
- 53.3% vs 12.8% NCT06230523
- 79.2% vs 12.8% NCT06230523
- MET-233i
- —Not reported
Waist circumference, change (cm)
- eloralintide
- —Trial running · NCT07321886
- MET-233i
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
MET-233i: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. eloralintide: 4 of 4 rows · MET-233i: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | eloralintide |
|---|---|
| Dropout rate | 20.8%6/9 mga NCT06230523 · Phase 2 show 5 more results11.1%9 mg NCT06230523 · Phase 2 25%6 mg NCT06230523 · Phase 2 20.8%3 mg NCT06230523 · Phase 2 46.4%1 mg NCT06230523 · Phase 2 11.5%3/6/9 mg NCT06230523 · Phase 2 |
| Discontinued due to AEs | 0%6/9 mga NCT06230523 · Phase 2 show 5 more results1.9%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 0%3 mg NCT06230523 · Phase 2 7.1%1 mg NCT06230523 · Phase 2 3.8%3/6/9 mg NCT06230523 · Phase 2 |
| Serious AEs | 8.3%6/9 mga NCT06230523 · Phase 2 show 5 more results5.6%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 4.2%3 mg NCT06230523 · Phase 2 10.7%1 mg NCT06230523 · Phase 2 1.9%3/6/9 mg NCT06230523 · Phase 2 |
| Most frequent reported AEs | 6/9 mga nausea 54.2% (placebo 13.2%) fatigue 45.8% (placebo 11.3%) upper respiratory tract infection 20.8% (placebo 11.3%) NCT06230523 · Phase 2 show 5 more results9 mg fatigue 42.6% (placebo 11.3%) nausea 33.3% (placebo 13.2%) constipation 24.1% (placebo 5.7%) NCT06230523 · Phase 2 6 mg nausea 64.3% (placebo 13.2%) diarrhoea 35.7% (placebo 9.4%) fatigue 28.6% (placebo 11.3%) NCT06230523 · Phase 2 3 mg constipation 16.7% (placebo 5.7%) arthralgia 12.5% (placebo 5.7%) fatigue 12.5% (placebo 11.3%) NCT06230523 · Phase 2 1 mg benign prostatic hyperplasia 14.3% (placebo 15.4%) constipation 14.3% (placebo 5.7%) covid-19 14.3% (placebo 3.8%) NCT06230523 · Phase 2 3/6/9 mg nausea 25% (placebo 13.2%) fatigue 21.2% (placebo 11.3%) diarrhoea 17.3% (placebo 9.4%) NCT06230523 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
eloralintide
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: eloralintide's landscape · MET-233i's landscape